- New
GHRP-2 is a specialised research peptide used in scientific investigation of growth hormone secretagogue activity, receptor-mediated signalling, and neuroendocrine regulatory pathways.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden.
Order before 15:00 for same day dispatch
Royal Mail Tracked 24
Moneyback guarantee
Synonyms / Designations: GHRP-2, Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102.
CAS Number: 158861-67-7.
Molecular Formula: C45H55N9O6
Molecular Weight: ~818.0 g/mol.
Purity: ≥ 99 % (HPLC).
Appearance: White to off-white lyophilised powder.
Pack Size: 10 mg (total).
Storage: Desiccated, protected from light, stored at –20 °C or below.
Solubility: Soluble in water and buffered aqueous solutions (e.g. PBS).
GHRP-2 is a synthetic hexapeptide belonging to the class of growth hormone secretagogues, widely utilised in biochemical and physiological research to study receptor-mediated signalling within the hypothalamic–pituitary axis. It functions primarily as an agonist of the growth hormone secretagogue receptor (GHS-R1a), a G-protein-coupled receptor expressed in both central and peripheral tissues.
In cellular and in vivo research systems, GHRP-2 activates GHS-R1a independently of endogenous growth hormone-releasing hormone (GHRH), leading to downstream intracellular signalling cascades involving calcium mobilisation and modulation of second messenger pathways. These effects make GHRP-2 a useful molecular tool for investigating receptor activation dynamics, neuroendocrine regulation, and peptide–receptor interactions.
In preclinical research settings, exposure to GHRP-2 has been associated with altered signalling along the hypothalamic–pituitary axis, with downstream effects dependent on experimental model, dose, and exposure conditions. As such, GHRP-2 is commonly employed in mechanistic studies exploring peptide hormone signalling and receptor pharmacology.
| Parameter | Typical Value / Range |
|---|---|
| Purity (HPLC) | ≥ 99 % |
| Appearance | White to off-white lyophilised powder |
| Molecular Weight | ~818.0 g/mol |
| Peptide Type | Synthetic hexapeptide |
| Solubility | Water, buffered aqueous solutions |
| Storage | –20 °C, desiccated, dark |
| Pack Size | 3000 mg (research scale); bulk available |
Bowers C.Y. et al. Growth hormone–releasing peptide (GHRP). Cellular and Molecular Life Sciences.
https://pubmed.ncbi.nlm.nih.gov/10604470/
Howard A.D. et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science.
https://pubmed.ncbi.nlm.nih.gov/8700211/
Ghigo E. et al. Growth hormone–releasing peptides. European Journal of Endocrinology.
https://pubmed.ncbi.nlm.nih.gov/9010514/
Kojima M. et al. Ghrelin is a growth hormone–releasing acylated peptide from stomach. Nature.
https://pubmed.ncbi.nlm.nih.gov/10541310/
Keywords: GHRP-2, GHRP2, Pralmorelin, Growth Hormone Releasing Peptide-2
Your review appreciation cannot be sent
Report comment
Report sent
Your report cannot be sent
Write your review
Review sent
Your review cannot be sent
Reference: GHKCU50
Reference: BPC15710
Reference: EPITH10
GHRP-2 is a specialised research peptide used in scientific investigation of growth hormone secretagogue activity, receptor-mediated signalling, and neuroendocrine regulatory pathways.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden.
check_circle
check_circle